PubMed HealthSearch

Biomedical subjects

R W Frater

Publications and source records attributed to R W Frater.

At least 19 recordsLinked to original sources

Inverted Y incision for accurate tailoring of patches and vessels.

When anastomosing vessels or using a patch to close a defect, it is often difficult to trim the vessel end or patch to size once the anastomosis is underway. We describe an inverted Y technique that is easy, is completely reproducible, and provides for an even, accurate fit. A continuous suture is run from the heel along either side to the widest part of the anastomosis. A straight incision is made from the tip of the patch or toe of the vessel to a point corresponding to the apex of the defect to be filled; from this point, approximately curved cuts are made to the edges of the patch or vessel just beyond the last sutures. The patch is now accurately shaped and the suture lines are completed.

Anastomosis, Surgical

Diphenylhydantoin inhibits calcification of bovine pericardial implants and myocardium: a preliminary study.

Calcification is a major cause of glutaraldehyde-fixed bioprosthetic valve failure. Recent studies have shown that dystrophic calcification shares basic features with normal bone mineralization, including crystal initiation through the mediation of cell membranes, usually in the form of extracellular vesicles. In this study, we observed that calcification of the myocardium of DBA/2J mice was inhibited or reversed by diets supplemented with 100 mg/kg diet diphenylhydantoin (dilantin) for 70 days, with a calcification incidence of 25% in the dilantin group versus 58% in control. We further studied the effects of dilantin on bioprosthetic valve calcification. Three groups of young male Sprague-Dawley rats (100 g, 9/group) were implanted subcutaneously with 1-cm2 pieces of glutaraldehyde-fixed bovine pericardium. Controls were fed a ground chow for 45 or 90 days postimplantation; experimentals received the same chow for the first 45 days postimplantation and then were fed the same diet supplemented with 1000 mg dilantin/kg for the succeeding 45 days. Calcium content (microgram/mg dry weight) of the implants in the dilantin group was 137 +/- 18.6 versus 214 +/- 34.3 in 90 days control and 79.9 +/- 41.5 in 45 days control (mean +/- SD, P < 0.01 and P < 0.05 respectively, t test). The tibia calcium content of the dilantin group was not significantly different from 90 days control. We conclude that orally administered dilantin inhibits calcification of glutaraldehyde-fixed bovine pericardial implants preferentially. It does not cause decalcification either of implants that have already calcified or of the bones. The anti-calcification effect of dilantin may be associated with its anti-vitamin D effect.

Animals

Spontaneous host endothelial growth on bioprostheses. Influence of fixation.

BACKGROUND: Neither homografts nor bioprostheses have previously been seen to acquire a host endothelium. We previously reported a direct relation between aldehyde tanning and bioprosthesis calcification and the absence of calcification in the absence of aldehyde. METHODS AND RESULTS: Bovine pericardium was 1) treated with 0.625% glutaraldehyde and stored in 4% formaldehyde, 2) treated with 99.5% glycerol, and 3) treated with 99.5% glycerol and stored in formaldehyde (0.25-4%). The treated pericardium was used to construct stentless mitral valve prostheses (of a single pattern) that were implanted in weanling sheep. After the animals were killed, a strip of anterior cusp from annulus to papillary muscle was processed and examined by scanning electron microscopy for the presence of host endothelial growth. Avoidance of aldehyde allowed host endothelial growth in all cases (six of six), and pure aldehyde treatment inhibited growth in five of six animals. Exposure to aldehyde after glycerol treatment interfered with endothelialization significantly; after longer periods of implantation, however, endothelial growth occurred almost invariably in this group (12 of 13 implanted longer than 200 days). For this group, there was a statistically significant difference for duration of implantation between the valves that grew endothelium and those that did not (218.4 +/- 61.9 versus 128.5 +/- 65.4 days). CONCLUSIONS: Aldehyde treatment inhibits endothelial growth. With glycerol treatment, growth is uniformly present. Limited exposure to aldehydes after glycerol treatment inhibits endothelial growth, but this effect was ameliorated by prolonged implantation. The possibility of host endothelium-covered, noncalcifying bioprostheses is now real.

Animals

Mechanism of reduction of mitral regurgitation with vasodilator therapy.

Acute mitral regurgitation was produced in six open chest dogs by excising a portion of the anterior valve leaflet. Electromagnetic flow probes were placed in the left atrium around the mitral anulus and in the ascending aorta to determine phasic left ventricular filling volume, regurgitant volume and stroke volume. The systolic pressure gradient was calculated from simultaneously measured high fidelity left atrial and left ventricular pressures. The effective mitral regurgitant orifice area was calculated from Gorlin's hydraulic equation. Infusion of nitroprusside resulted in a significant reduction in mitral regurgitation. No significant change occurred in the systolic pressure gradient between the left ventricle and the left atrium because both peak left ventricular pressure and left atrial pressure were reduced. The reduction of mitral regurgitation was largely due to reduction in the size of the mitral regurgitant orifice. Reduction of ventricular volume rather than the traditional concept of reduction of impedance of left ventricular ejection may explain the effects of vasodilators in reducing mitral regurgitation.

Animals

Dynamic aspects of acute mitral regurgitation: effects of ventricular volume, pressure and contractility on the effective regurgitant orifice area.

The dynamics of acute mitral regurgitation were studied in six open-chest dogs in whom a portion of the anterior leaflet was excised. Phasic mitral and aortic flows were measured electromagnetically and left ventricular filling volume, regurgitant volume (RV) and forward stroke volume (SV) were calculated. The systolic pressure gradient (SPG) between the left ventricle (LV) and left atrium (LA) was obtained from high-fidelity pressure transducers. The effective mitral regurgitant orifice area (MRA) was calculated from the hydraulic equation of Gorlin. Volume infusion resulted in significant increases in both left atrial and left ventricular pressures; thus, the SPG was unchanged and the increase in RV was due primarily to the increase in MRA. Angiotensin infused to raise arterial pressure resulted in greater increments in left ventricular than left atrial pressure, so that SPG rose significantly. The increase in RV was due to increases in both MRA and SPG. Norepinephrine infusion increased systolic left ventricular pressure and SPG, while left ventricular end-diastolic pressure and left atrial pressure diminished. Despite a significant increase in SPG, RV did not increase, due to a substantial decrease in MRA. Thus, angiotensin and volume infusion induced a substantial increase in regurgitation due to the increase in MRA, while augmentation of contractility after norepinephrine infusion resulted in a decrease in regurgitation through reduction of MRA. These findings support the clinical view that maintaining a small LV with sustained myocardial contractility will reduce mitral regurgitation. Alternatively, left ventricular dilatation can enhance mitral regurgitation by increasing the effective regurgitant orifice independent of SPG.

Angiotensin II

In vitro hydrodynamic comparison of mitral valve bioprostheses.

With the use of the pulse duplicator built in our laboratory, the hydrodynamic characteristics of three sizes of the four commercially available mitral bioprostheses, Hancock, Carpentier-Edwards, Angell-Shiley, and Ionescu-Shiley, were studied and compared. A wide range of performance was found: for example, during pulsatile testing, at peak flow of 15 1/min (corresonding to a normal resting cardiac output) transvalvular gradients varied from as high as 20 mm Hg (Angell-Shiley) to 5 mm Hg(Ionescu-Shiley) in the 25 mm mounting diameter size. Effective orifice areas (EOA) are significantly different in valves of the same mounting size, e.g., at peak flows of 20 1/min, the Ionescu-Shiley 25 provides an EOA of 1.7 cm2 while the Angell-Shiley provides only 1.17 cm2. The EOAs of all bioprostheses have been found to increase with increasing flow (e.g., from 10--30 1/min peak flow, the Hancock 25 changed from 1.25 cm2 to 1.50 cm2). The Gorlin formula, as constituted for calculating the area of stenotic mitral valves, is inappropriate for prosthetic valves. But the discharge coefficients of the bioprostheses have been found to be around 1 when the planimetered area of the open valve orifice is determined at a given flow. By using this discharge coefficient, the Gorlin formula will give an excellent estimate of the true orifice area of mitral bioprostheses.

Bioprosthesis

Dynamic changes in the canine mitral regurgitant orifice area during ventricular ejection.

We designed this study to test the hypothesis that in acute mitral regurgitation the mitral regurgitant area (MRA) is a dynamic quantity which varies with the time variation of ventricular volume. Mitral insufficiency was created in five open-chest dogs in which a portion of the anterior leaflet was excised. Phasic aortic and mitral flows were measured electromagnetically, along with left atrial and ventricular pressures. Filling, regurgitant, and stroke volumes, and systolic pressure gradient were determined by digital methods. MRA was calculated from the fluid dynamic equation of motion to give the temporal mean and the instantaneous value at three instants of time and at the time of peak flow (when inertia is negligible). Mean regurgitant fraction was 42 +/- 12% with no indication of left ventricular failure due to volume overload. MRA decreased monotonically with time to 59% of its initial value and closely paralleled the decrease in ventricular volume during systole. In a control study using a tilting-disc prosthesis with a hole 5 mm in diameter in the occluder, the calculated MRA was time invariant and equal to the measured area for regurgitation. We conclude that in acute mitral regurgitation the MRA is a function of ventricular volume.

Animals

beta-Blockade therapy for supraventricular tachyarrhythmias after coronary surgery: a propranolol withdrawal syndrome?

A high incidence of cardiac arrhythmias and hypertension has been noted after coronary artery bypass surgery in patients previously treated with oral propranolol. Forty-two patients undergoing coronary bypass surgery had propranolol withdrawal 10 hours before surgery and were randomized into a group treated with propranolol immediately postoperatively, and a nontreatment group. Patients treated with prophylactic propranolol had a significantly lower incidence of postoperative supraventricular arrhythmias compared to patints who received no prophylaxis. All the arrhythmias responded rapidly to 1 mg of intravenous propranolol therapy, whether it was used as a primary treatment or as a supplement to prophylactic propranolol. The findings suggest that (1) there is a high incidence of supraventricular arrhythmias and sinus tachycardia after coronary artery bypass which might reflect an abrupt propranolol withdrawal, and (2) that perioperative prophylactic or supplementary propranolol therapy will successfully prevent or treat most of these arrhythmias.

Coronary Artery Bypass

Surgery for mitral valve endocarditis.

The records of 20 patients who underwent mitral valve replacement for complications of bacterial endocarditis were reviewed. Although the indications for surgery were the same as those for patients with aortic endocarditis, major emboli (cerebral, coronary or retinal) prompted surgery in 8 of 20 patients, a much higher incidence than reported for surgery in aortic valve endocarditis. Eighteen of the patients had mitral regurgitation; 14 of these had severe congestive heart failure, but the development of congestive failure tended to be more insidious than in patients with aortic endocarditis. Continued septicemia despite appropriate antibiotics was the least common indication for surgery. Sixteen of the 20 patients were salvaged by surgery, although some had major residual deficits, related mainly to preoperative emboli. These results are a marked improvement in the expected 90-100 percent mortality rate for patients with these complications of endocarditis. The main reason for a poor result following surgery was temporization leading to continued deterioration of vital functions preoperatively. Reinfection of the prosthesis did not occur, and we do not consider duration of preoperative antibiotic therapy an important factor in the decision to perform surgery.

Adult

In vitro hydrodynamic comparison of mitral valve prostheses at high flow rates.

A pulse duplicator system for evaluating the hemodynamic performance of mitral prostheses is described. Under conditions stimulating normal resting physiology, all valves tested had measurable but acceptably small pressure drops. Under conditions simulating exercise, all were moderately to severely stenotic. Valves with nearly equal mounting diameters were compared. The Hancock, Beall, and Starr-Edwards valves (Group A) were found to be significantly more stenotic than the Björk-Shiley, Cutter-Cooley, Ionescu-Shiley, and Lillehei-Kaster valves (Group B). In the 29 to 30 mm. mounting diameter size at cardiac outputs of 5 and 9 L. per minute, Group A had average pressure drops of 3.2 and 10.5 mm. Hg and Group B, pressure drops of 1.6 and 5.3 mm. Hg, respectively. In the 24 to 26 mm. mounting diameter size, at cardiac outputs of 9 L. per minute, all the valves had critically large pressure drops (9 to 17.6 mm. Hg). The standard Gorlin formula is inappropriate for computing the orifice area of prosthetic valves. The discharge coefficient for a valve (a measure of how well the valve uses its primary flow area) and a performance index (a measure of how well the valve uses its mounting area) have been computed from a knowledge of the orifice size, without the necessity of assuming a value for the discharge coefficient required by the Gorlin formula. The biological valves (Hancock and Ionescu-Shiley) provide an efficient orifice for fluid flow at the free leaflet margins and have large discharge coefficients. On the basis of the fluid dynamic equation of motion, steady flow, root mean square (RMS) flow, and peak flow, combined with the appropriate transvalvular gradients, were all shown to yield equally accurate characterizations of valvular hydrodynamic performance. Mean flow, unfortunately the only value obtainable clinically, yielded effective orifice areas 10 percent smaller than either of the other three flow values.

Bioprosthesis

The subxiphoid approach in the treatment of pericardial effusion.

Subxiphoid pericardiotomy for diagnosis and treatment of pericardial effusion is a safe procedure. Not only does it appear to be safer than aspiration, but it yields more information because of its ability to obtain pericardial tissue. The recurrence rate of pericardial effusion is lower using subxiphoid pericardiotomy. For these reasons it is the technique of choice for diagnosis and treatment of nontraumatic pericardial effusion.

Drainage